These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

585 related articles for article (PubMed ID: 23198454)

  • 21. Other antimicrobials of interest in the era of extended-spectrum beta-lactamases: fosfomycin, nitrofurantoin and tigecycline.
    Garau J
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():198-202. PubMed ID: 18154548
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aminoglycoside therapy for childhood urinary tract infection due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae.
    Han SB; Lee SC; Lee SY; Jeong DC; Kang JH
    BMC Infect Dis; 2015 Oct; 15():414. PubMed ID: 26464143
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Extended spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae isolated in a rural hospital.
    Basak S; Mallick SK; Bose S
    J Indian Med Assoc; 2009 Dec; 107(12):855-8. PubMed ID: 20509468
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Extended-spectrum beta-lactamase-producing phenotype signifies a poor prognosis for patients with cefpodoxime-resistant Escherichia coli or Klebsiella pneumoniae bacteremia.
    Lee CI; Lee NY; Yan JJ; Lee HC; Ko NY; Chang CM; Wu CJ; Chen PL; Wang LR; Ko WC
    J Microbiol Immunol Infect; 2009 Aug; 42(4):303-9. PubMed ID: 19949753
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence and antimicrobial susceptibility of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a general hospital.
    Kader AA; Kumar A
    Ann Saudi Med; 2005; 25(3):239-42. PubMed ID: 16119526
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Activity of fosfomycin against extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae].
    de Cueto M; Hernández JR; López-Cerero L; Morillo C; Pascual A
    Enferm Infecc Microbiol Clin; 2006 Dec; 24(10):613-6. PubMed ID: 17194386
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro susceptibility pattern of cephalosporin-resistant Gram-negative bacteria.
    Punpanich W; Tantichattanon W; Wongwatcharapaiboon S; Treeratweeraphong V
    J Med Assoc Thai; 2008 Oct; 91 Suppl 3():S21-7. PubMed ID: 19255989
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibacterial activity of fosfomycin against uropathogens.
    Sun F; Chen S; Qiu X; Sun Y; Feng W; Chen J; Xia P
    Chemotherapy; 2014; 60(3):157-61. PubMed ID: 25792115
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalent phenotypes and antibiotic resistance in Escherichia coli and Klebsiella pneumoniae at an Indian tertiary care hospital: plasmid-mediated cefoxitin resistance.
    Shahid M; Malik A; Akram M; Agrawal LM; Khan AU; Agrawal M
    Int J Infect Dis; 2008 May; 12(3):256-64. PubMed ID: 17981482
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Aspects of the antimicrobial resistence profile in infections with Escherichia coli and Klebsiella pneumoniae in diabetic patients].
    Petrovici CG; Dorobăţ C; Matei M; Teodor A; Luca V; Miftode E
    Rev Med Chir Soc Med Nat Iasi; 2011; 115(3):769-75. PubMed ID: 22046785
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Control of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a children's hospital by changing antimicrobial agent usage policy.
    Lee J; Pai H; Kim YK; Kim NH; Eun BW; Kang HJ; Park KH; Choi EH; Shin HY; Kim EC; Lee HJ; Ahn HS
    J Antimicrob Chemother; 2007 Sep; 60(3):629-37. PubMed ID: 17599919
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy.
    Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Kim EC; Oh MD; Choe KW
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4574-81. PubMed ID: 15561828
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Antibiotic resistance rates of extended spectrum beta-lactamase producing Escherichia coli and Klebsiella spp. strains isolated from urinary tract infections in a private hospital].
    Akyar I
    Mikrobiyol Bul; 2008 Oct; 42(4):713-5. PubMed ID: 19149097
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in spanish hospitals (GEIH-BLEE Project 2002)].
    Hernández JR; Pascual A; Cantón R; Martínez-Martínez L;
    Enferm Infecc Microbiol Clin; 2003 Feb; 21(2):77-82. PubMed ID: 12586030
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes.
    Lautenbach E; Patel JB; Bilker WB; Edelstein PH; Fishman NO
    Clin Infect Dis; 2001 Apr; 32(8):1162-71. PubMed ID: 11283805
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ESBL-producing Escherichia coli and Klebsiella pneumoniae at a tertiary care hospital in Saudi Arabia.
    Somily AM; Habib HA; Absar MM; Arshad MZ; Manneh K; Al Subaie SS; Al Hedaithy MA; Sayyed SB; Shakoor Z; Murray TS
    J Infect Dev Ctries; 2014 Sep; 8(9):1129-36. PubMed ID: 25212077
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Susceptibility to Fosfomycin and Nitrofurantoin of ESBL-Positive
    Park KS; Kim DR; Baek JY; Shin A; Kim KR; Park H; Son S; Cho H; Kim YJ
    J Korean Med Sci; 2023 Dec; 38(48):e361. PubMed ID: 38084025
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epidemiology and risk factors for extended-spectrum beta-lactamase-producing organisms: a case control study at a tertiary care center in Lebanon.
    Kanafani ZA; Mehio-Sibai A; Araj GF; Kanaan M; Kanj SS
    Am J Infect Control; 2005 Aug; 33(6):326-32. PubMed ID: 16061138
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence and antimicrobial resistance patterns of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolated from blood cultures in an Istanbul University Hospital.
    Koksal F; Ak K; Kucukbasmaci O; Samasti M
    Chemotherapy; 2009; 55(4):293-7. PubMed ID: 19521075
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro activity of fosfomycin against ciprofloxacin-resistant or extended-spectrum beta-lactamase-producing Escherichia coli isolated from urine and blood.
    Ko KS; Suh JY; Peck KR; Lee MY; Oh WS; Kwon KT; Jung DS; Lee NY; Song JH
    Diagn Microbiol Infect Dis; 2007 May; 58(1):111-5. PubMed ID: 17300900
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.